Investigators: Roland Griffiths PhD, William Richards PhD, Matthew Johnson, Ph.D., Una McCann, M.D. Sponsor: Heffter Research Institute, Riverstyx Foundation Contact: Roland Griffiths, PhD Status: Completed …
Investigator: Francisco Moreno, MD University of Arizona, Tucson, USA Contact: Francisco Moreno, MD Sponsor: Heffter/MAPS This is the first FDA-approved study in more than 25 years to examine the use …
Investigator: Charles Grob, MD, UCLA-Harbor Medical Center – Torrance, CAContact: cgob at labiomed.orgWeb: JAMA PsychiatrySponsor: HeffterGrob has prepared a study investigating whether anxiety in …
Investigators: Robin Carhart-Harris, Ph.D., Richard Wise, Amanda Feilding, David Nutt, Ph.D. Sponsor: Beckley Foundation Supporting sponsor: MAPS and Heffter Research Institute Contact: Robin Carhart Harris …
Investigators: Torsten Passie M.D., Jrgen Seifert M.D., Udo Schneider M.D., Hinderk M. Emrich M.D., Ph.D. Medical School Hannover, Dept. of Clinical Psychiatry and Psychotherapy, Hannover, Germany Contact: …
Investigator: Franz Vollenweider, MD Psychiatric University Hospital Zurich, Switzerland Contact: Sponsor: Heffter Dr. Vollenweider’s team have completed a series of basic research studies into the …
Investigator: Rick Doblin, Ph.D. This study, originally published in the Journal of Psychoactive Drugs [Oct-Dec 1998] is one in a series of long-term follow-ups to early psychedelic research that MAPS …
Investigator: Rick Strassman, MD University of New Mexico, USA Psychobiological study. Phase 1 dose-response study Sponsor: NIDA Begun, not completed due to personal reasons unrelated to study itself. …
Investigator: Manfred Spitzer, MD, PhD et al. Psychiatrische Universitats Klinic, Heidelberg, Germany Human clinical study, completed and published. More psilocybin research in Germany Spitzer M, et al. …
Investigator: Rick Strassman, MD University of New Mexico, USA Psychobiological study. Phase 1 dose-response study Sponsor: NIDA Begun, not completed due to personal reasons unrelated to study itself. …
